No Data
Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank
Keros Therapeutics Price Target Cut to $44.00/Share From $77.00 by Scotiabank
Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84
Tooleye3 OP : - YouTube